Form 4: Edwards Lifesciences CFO Exercises Options and Sells Shares Under 10b5-1 Plan

Edwards Lifesciences' Chief Financial Officer, Scott B. Ullem, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• Scott B. Ullem, the Chief Financial Officer of Edwards Lifesciences, executed transactions involving the company's common stock on December 9, 2024.
• Ullem exercised 11,250 employee stock options at a price of $45.2767 per share.
• Following the exercise, Ullem sold 11,250 shares of common stock at a weighted average price of $71.6805 per share.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on August 19, 2024.
• After these transactions, Ullem directly owns 30,561 shares and indirectly owns 266,318 shares through a trust.

Sentiment

Score: 5

Explanation: The document reflects routine insider trading activity under a pre-arranged plan, which is neither positive nor negative for the company's overall outlook.

Industry Context

This is a routine filing related to insider trading activity, which is common for executives of publicly traded companies. The use of a 10b5-1 plan indicates a pre-planned strategy for stock transactions.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies like Edwards Lifesciences, including competitors such as Medtronic and Abbott.
• These plans allow insiders to sell shares without being accused of trading on non-public information.
• The reported transactions are typical for executives exercising stock options and selling shares for personal financial management.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are part of a pre-planned trading strategy.
• The sale of shares by the CFO may slightly increase the available float of the stock.

Key Dates

Keywords

insider trading, stock options, Rule 10b5-1, stock sale, beneficial ownership, Edwards Lifesciences, CFO, Scott B. Ullem